Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 26;7(24):7621-7623.
doi: 10.1182/bloodadvances.2023011867.

Celebrating a year of cancer research in Blood Advances

Catherine M Bollard  1 , Andrew Weyrich  2
Affiliations

Celebrating a year of cancer research in Blood Advances

Catherine M Bollard et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.M.B. and A.S.W. declare no competing financial interests with the manuscripts presented.

References

    1. Salaverria I, Weigert O, Quintanilla-Martinez L. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas. Blood Adv. 2023;7(18):5258–5271. - PMC - PubMed
    1. Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774–5785. - PMC - PubMed
    1. Schinke C, Poos AM, Bauer M, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6(22):5873–5883. - PMC - PubMed
    1. Konopleva MY, Röllig C, Cavenagh J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6(14):4147–4156. - PMC - PubMed
    1. Gagelmann N, Wulf GG, Duell J, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv. 2023;7(4):555–559. - PMC - PubMed